|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
| Title: | Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma |
| Authors: | Yang, Zijian Browse this author | | Suda, Goki Browse this author →KAKEN DB | | Maehara, Osamu Browse this author | | Ohara, Masatsugu Browse this author | | Yoshida, Sonoe Browse this author | | Hosoda, Shunichi Browse this author | | Kimura, Megumi Browse this author | | Kubo, Akinori Browse this author | | Tokuchi, Yoshimasa Browse this author | | Fu, Qingjie Browse this author | | Yamada, Ren Browse this author | | Kitagataya, Takashi Browse this author | | Suzuki, Kazuharu Browse this author | | Kawagishi, Naoki Browse this author | | Nakai, Masato Browse this author | | Sho, Takuya Browse this author | | Natsuizaka, Mitsuteru Browse this author | | Morikawa, Kenichi Browse this author | | Ogawa, Koji Browse this author | | Ohnishi, Shunsuke Browse this author | | Sakamoto, Naoya Browse this author →KAKEN DB |
| Keywords: | post progressive survival | | lenvatinib | | HCC | | growth factors | | prognosis |
| Issue Date: | 4-Jan-2022 |
| Publisher: | MDPI |
| Journal Title: | Cancers |
| Volume: | 14 |
| Issue: | 1 |
| Start Page: | 232 |
| Publisher DOI: | 10.3390/cancers14010232 |
| Abstract: | Simple Summary In this study, we firstly revealed that the pattern of developing resistance to lenvatinib varies and determines the prognosis of patients with unresectable hepatocellular carcinoma (HCC) by analyzing the changes in growth factors during lenvatinib for unresctable HCC. The evaluation of changes in growth factors during lenvatinib could predict treatment response and PPS and could be used for the determination of salvage therapy. Serum growth factor changes and their effect on prognosis during lenvatinib for unresectable hepatocellular carcinoma (HCC) remain underexplored. The sequential changes in serum growth factors during lenvatinib for unresectable HCC were evaluated in 58 patients using complete clinical data, and preserved serum was used to investigate changes in FGF-19, ANG-2, HGF, VEGF, and EGF. Patients with a complete response (CR), partial response (PR), and stable disease (SD) were evaluated for growth factor changes between the best response and progressive disease (PD) points, classified based on these changes, and evaluated by post progression survival (PPS). A total of 8, 24, 18, and 8 patients showed CR, PR, SD, and PD, respectively. Multivariate analysis revealed that age, relative dose intensity, and baseline ANG-2 were significantly associated with treatment response. Growth factor changes between the best response and PD points revealed that patients could be classified into four groups based on the EGF, ANG-2, and HGF changes. Although patient characteristics at baseline and PD, their response to lenvatinib, and PFS were similar among those groups, patients with an increase in all growth factors had significantly shorter PPS (median PPS was 553, 323, and 316 versus 173 days in groups 1-4 p = 0.032). We revealed that the evaluation of the changes in growth factors during lenvatinib could predict PPS. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/84259 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
